MT-2990
- Generic Name
- MT-2990
An Exploratory Study of MT-2990 in Patients With AAV
Phase 1
Recruiting
- Conditions
- Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT06196905
- Locations
- π―π΅
Kagawa University Hospital, Kita-gun, Kagawa, Japan
π―π΅Saitama Medical Center, Kawagoe, Saitama, Japan
π―π΅Hiroshima University Hospital, Hiroshima-shi, Hiroshima, Japan
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT03840993
- Locations
- πΊπΈ
Medi-Sense, Atlanta, Georgia, United States
πΊπΈDrug Studies America - Marietta, Marietta, Georgia, United States
πΊπΈClinical Research Prime, Idaho Falls, Idaho, United States
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT03570957
- Locations
- π―π΅
Investigational Site, Tokyo, Japan
A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT03156738
- Locations
- π³π±
Pharmaceutical Research Associates (PRA) Health Sciences, NZ Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath